Abstract
Purpose :
Online reporting helps by comparing results, thereby, improving health care standards. This programme provides real-world data on the world-wide-web for patient and doctor awareness.
Methods :
From December’2017 to December’2022, patients with choroidal melanoma (CM), iridociliary melanoma (ICM) and ocular surface squamous carcinoma (OSSC) had specific outcomes recorded at each return visit. Data was entered into a HIPAA compliant, internet-based software program. Each result was anonymized, entered in an online portal and sent to this unique software program developed to create real-world-data i.e., numbers (count), most common (median) and averages (mean) regarding number of patients, vision, local tumor control, eye salvage, metastases and follow-up time for our eye cancer specialty center. The results were linked to public access webpage revealing near-real-time data pertaining to vision, life and follow-up time of eye cancer patients.
Results :
On December 31st 2022, the mean CM tumor control was 99.7%, mean vision was 20/63 (median vision 20/25) and eye salvage rate was 96.6% with an average follow-up of 8.2 years. ICM tumor control was 99.1% with mean vision of 20/20 (median vision 20/20) with 7.5 years of average follow-up. OSSC tumor control was 98.4% with mean vision of 20/32 (median 20/20) and average follow-up of 2.4 years. Rates of primary enucleation were 3.4% for CM, 1.7% for ICM and 0% for OSSC. Results were near-real-time automatically updated on the web page. Our local control rates were higher than expected.
Conclusions :
Online reporting helped both patients and physicians transparently access near-real-time single center results. DRO knowledge enlightened our eye cancer specialists and improved informed consent. This software is open-access for ophthalmic oncology. Multi-center implementation of this DRO system offers the potential to improve patient care.
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.